A combination of p300 and Braf expression in the diagnosis and prognosis of melanoma

A combination of p300 and Braf expression in the diagnosis and prognosis of melanoma

Bibliographic Details
Main Authors:	Bhandaru, Madhuri, Ardekani, Gholamreza Safaee, Zhang, Guohong, Martinka, Magdalena, McElwee, Kevin J, Li, Gang, Rotte, Anand
Format:	Online
Language:	English
Published:	BioMed Central 2014
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4051389/

Similar Items

Prognostic Significance of Nuclear Phospho-ATM Expression in Melanoma
by: Bhandaru, Madhuri, et al.
Published: (2015)

Decreased Expression of Nuclear p300 Is Associated with Disease Progression and Worse Prognosis of Melanoma Patients
by: Rotte, Anand, et al.
Published: (2013)

Stage-specific prognostic biomarkers in melanoma
by: Cheng, Yabin, et al.
Published: (2015)

Loss of tumor suppressors KAI1 and p27 identifies a unique subgroup of primary melanoma patients with poor prognosis
by: Zhang, Guohong, et al.
Published: (2015)

High LIFr expression stimulates melanoma cell migration and is associated with unfavorable prognosis in melanoma
by: Guo, Hongwei, et al.
Published: (2015)

Sox4 Mediated Dicer Expression is Critical for Suppression of Melanoma Cell Invasion
by: Jafarnejad, Seyed Mehdi, et al.
Published: (2012)

The Prognostic Value of BRAF Mutation in Colorectal Cancer and Melanoma: A Systematic Review and Meta-Analysis
by: Safaee Ardekani, Gholamreza, et al.
Published: (2012)

C-Terminal Tensin-Like Protein Is a Novel Prognostic Marker for Primary Melanoma Patients
by: Sjoestroem, Cecilia, et al.
Published: (2013)

BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance
by: Sullivan, Ryan J., et al.
Published: (2011)

Dabrafenib for treatment of BRAF-mutant melanoma
by: Kainthla, Radhika, et al.
Published: (2013)

Connecting the P300 to the diagnosis and prognosis of unconscious patients
by: Li, Ran, et al.
Published: (2015)

Increased expression of neuropilin 1 in melanoma progression and its prognostic significance in patients with melanoma
by: LU, JING, et al.
Published: (2015)

Novel combination therapies for BRAF-mutant melanoma
by: McArthur, Grant A
Published: (2015)

Optimizing the treatment of BRAF mutant melanoma
by: Settleman, Jeff
Published: (2014)

The immune‐related role of BRAF in melanoma
by: Tomei, Sara, et al.
Published: (2014)

The immune-related role of BRAF in melanoma
by: Tomei, Sara, et al.
Published: (2015)

Electrochemotherapy with bleomycin is effective in BRAF mutated melanoma cells and interacts with BRAF inhibitors
by: Dolinsek Tanja, et al.
Published: (2016-09-01)

Electrochemotherapy with bleomycin is effective in BRAF mutated melanoma cells and interacts with BRAF inhibitors
by: Dolinsek, Tanja, et al.
Published: (2016)

Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
by: Smalley, Keiran SM, et al.
Published: (2015)

BET and BRAF inhibitors act synergistically against BRAF‐mutant melanoma
by: Paoluzzi, Luca, et al.
Published: (2016)

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
by: Spagnolo, Francesco, et al.
Published: (2014)

Efficacy of BRAF Inhibitors in Asian Metastatic Melanoma Patients: Potential Implications of Genomic Sequencing in BRAF-Mutated Melanoma12
by: Kim, Hee Kyung, et al.
Published: (2016)

Expression of the RNase III enzyme DROSHA is reduced during progression of human cutaneous melanoma
by: Jafarnejad, Seyed Mehdi, et al.
Published: (2013)

Clinical significance of BRAF mutations in metastatic melanoma
by: Chang, David Z, et al.
Published: (2004)

Polymorphisms of the BRAF gene predispose males to malignant melanoma
by: Meyer, Peter, et al.
Published: (2003)

The role of BRAF V600 mutation in melanoma
by: Ascierto, Paolo A, et al.
Published: (2012)

Frequency of BRAF Mutation and Clinical Relevance for Primary Melanomas
by: Lee, Hyoun Wook, et al.
Published: (2012)

BRAF and beyond: Tailoring strategies for the individual melanoma patient
by: Jarkowski, Anthony, et al.
Published: (2014)

BRAF-targeted therapy and immune responses to melanoma
by: Ngiow, Shin Foong, et al.
Published: (2013)

Variations of BRAF mutant allele percentage in melanomas
by: Hélias-Rodzewicz, Zofia, et al.
Published: (2015)

Beyond BRAF: where next for melanoma therapy?
by: Fedorenko, I V, et al.
Published: (2015)

Addressing the age-old question of old age
by: McElwee, Joshua J
Published: (2004)

A Structured Approach to Residential Workshop Organisation
by: Gerard, McElwee
Published: (1990)

A Study of the Reading Attainment of Children in Ungraded Classes
by: McElwee, Edna Willis
Published: (1931)

An Analysis of the Binet Test of Naming Words
by: McElwee, Edna Willis
Published: (1932)

The Selection of Candidates for Trade School from a Group of Subnormal Italian Girls
by: McElwee, Edna Willis
Published: (1932)

Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma
by: Birkeland, Einar, et al.
Published: (2013)

Therapeutic efficacy of combined BRAF and MEK inhibition in metastatic melanoma: a comprehensive network meta-analysis of randomized controlled trials
by: Mai, Ruiqin, et al.
Published: (2015)

Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma
by: Cooper, Zachary A., et al.
Published: (2013)

Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma
by: Homet Moreno, Blanca, et al.
Published: (2015)